HDL therapy for cardiovascular diseases: the road to HDL mimetics

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Statins effectively lower low-density lipoprotein (LDL) cholesterol but residual cardiac events occur. Low high-density lipoprotein (HDL) cholesterol is an independent cardiovascular risk factor.
• Current lipid-lowering therapies offer modest HDL elevation, often with adverse effects.
• Atherosclerosis and inflammation can impair HDL quality and function.

Purpose of the Study:

• To review the current landscape of HDL therapeutics.
• To highlight apolipoprotein A-I mimetic peptides as a novel therapeutic class.
• To discuss their potential to improve HDL function and reduce cardiovascular risk.

Main Methods:

• Review of existing clinical trial data on statins and other lipid-lowering therapies.
• Analysis of emerging research on HDL quality and function in disease states.
• Focus on the mechanism of action and therapeutic potential of apolipoprotein A-I mimetic peptides.

Main Results:

• Despite LDL lowering, significant cardiovascular events persist in statin-treated patients.
• HDL cholesterol levels are critical for cardiovascular risk assessment.
• Apolipoprotein A-I mimetic peptides demonstrate potential to enhance HDL functionality.

Conclusions:

• Elevating HDL cholesterol, particularly its functional capacity, is a promising strategy for cardiovascular risk reduction.
• Apolipoprotein A-I mimetic peptides represent a novel therapeutic avenue for improving HDL function.
• Further research into HDL-targeted therapies is warranted for comprehensive cardiovascular disease management.